TLDRs;
- Court ruling in South Africa blocks compounded semaglutide supply boosting Novo sentiment
- Investors expect shift toward branded Wegovy and Ozempic demand in region
- Share buybacks provide additional but limited support to Novo Nordisk stock
- Competition from Eli Lilly continues to pressure long term growth outlook
Novo Nordisk (NYSE:NVO) shares extended their upward momentum on Tuesday after a South African court ruling disrupted the supply of compounded semaglutide products, a move that investors interpreted as a potential tailwind for the company’s branded obesity and diabetes drugs, including Ozempic and Wegovy.
The stock gained 2.6% in Copenhagen trading to 307.75 Danish crowns, bringing its three-session advance to nearly 10%, even as the broader OMXC25 index slipped slightly. In the U.S., Novo’s ADRs also posted gains, rising 3.4% to $47.42, continuing a strong rebound driven by both legal developments and corporate capital returns.
Court blocks compounded supply chain
The latest catalyst came from a court order in South Africa that restricted iDexis from compounding, supplying, and marketing semaglutide-based products while regulatory review is ongoing. Compounding refers to pharmacies preparing or altering medications outside standard commercial packaging, often at lower cost.
Novo Nordisk told the court that iDexis was supplying roughly 84,500 compounded semaglutide units per month in the region, an amount the company claims exceeds its combined local sales of Ozempic and Wegovy. However, the filing did not clarify how those units compare directly to Novo’s branded packaging, leaving uncertainty around the precise revenue impact.
Even so, investors are treating the ruling as structurally meaningful. By limiting access to cheaper compounded alternatives, the decision could redirect demand toward regulated branded therapies, potentially strengthening Novo’s pricing power in a market where affordability has been a key constraint.
South Africa becomes key battleground
The South African GLP-1 market has been increasingly competitive, with Eli Lilly’s Mounjaro reportedly capturing more than half of the market earlier this year. Pricing pressure remains a defining factor, with Novo previously cutting the lowest Wegovy dose significantly in an attempt to improve accessibility.
Local market executives have acknowledged that initial pricing levels were not well aligned with regional purchasing power, forcing manufacturers to adjust strategies. The court ruling may temporarily tilt the playing field in favor of registered drugs, but analysts caution that patients and providers could still favor lower-cost alternatives if available.
This creates a complex outlook: while Novo may see short-term volume gains, long-term share capture will depend on whether pricing adjustments can compete with Lilly’s aggressive positioning.
Buybacks reinforce investor confidence
Beyond legal developments, Novo Nordisk’s ongoing share repurchase program has provided additional support to the stock. The company has already bought back nearly 21 million B shares since February at an average price of 266.09 crowns, amounting to over 5.5 billion crowns in capital deployment.
At current market levels, those repurchased shares have appreciated in value, reinforcing investor confidence in management’s capital allocation strategy. However, the scale of daily buybacks remains relatively small compared to total trading volume, suggesting that while supportive, they are not the primary driver of recent gains.
If fully executed, the remaining buyback authorization could further reduce float modestly, but analysts note it is unlikely to independently sustain the recent multi-session rally.
Outlook remains balanced amid competition
Despite the recent rally, Novo Nordisk still faces structural headwinds. Eli Lilly continues to be a strong competitor in the GLP-1 category, particularly in international markets where pricing and access are decisive factors.
Additionally, Novo’s broader 2026 guidance still signals potential declines in adjusted sales and operating profit on a constant currency basis, reflecting both pricing pressure and increased competition.
Still, the combination of regulatory disruption in South Africa, expanding access programs such as Medicare-linked copay reductions in the U.S., and continued demand for obesity treatments keeps investor attention firmly on the company’s long-term growth narrative.
For now, the market is weighing short-term legal tailwinds against longer-term competitive realities, making Novo Nordisk one of the most closely watched pharmaceutical stocks in the GLP-1 race.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
